Concepedia

Deqi Guo

DG

Statistics

Publications

9

Citations

269

H-Index

9

Active since

1992

Affiliations

Eli Lilly (United States)(Current)

National Research Council Canada

NAEJA-RGM Pharmaceuticals (Canada)

Deqi Guo is an author at Eli Lilly (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1992–2021

9

Publications

9

3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors

Nian Zhou, Deqi Guo, George Thomas et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 67 citations · Full text

, , +11

Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor

Sheng-Bin Peng, Chong Si, Youyan Zhang et al. · Cancer Research · 2021 · 45 citations

, , +15

Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR

Jason Lamar, Jingdan Hu, Ana B. Bueno et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 33 citations · Full text

, , +14

P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl α-ketoamide based HCV protease inhibitors

Frantz Victor, Jason Lamar, Nancy Snyder et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 32 citations · Full text

, , +12

P3 cap modified Phe*-Ala series BACE inhibitors

Shuhui Chen, Jason Lamar, Deqi Guo et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 25 citations · Full text

, , +6

1–5 of 9